Acute renal failure

Low-dose "renal" dopamine

Low dose renal dopamine continues to be infused in patients at risk for renal dysfunction or as a therapy after acute renal failure has been established. This article reviews the impact of acute renal failure on patients and reviews the history and use of dopamine therapy for patients. A discussion of the rationale, positive and equivocal evidence, side effects, and possible clinical indications for low-dose renal dopamine therapy is included.

Anesthesia for kidney transplant surgery

Organ viability associated with renal transplantation is a product of the managing of the donor patient, the allograft, and the recipient patient. Short- and long-term outcome is influenced by perioperative fluid and drug treatment, and the function and viability of the transplanted kidney seem to be optimized if graft perfusion is maximized through mild hypervolemia. At the same time, careful balancing of intraoperative fluids is necessary against cardiovascular problems frequently encountered in patients with uremia. Close intraoperative monitoring, optimization of intravascular fluid volume status to maximize kidney perfusion, and prompt correction of electrolyte disturbances (especially potassium) are key to short- and long-term success of renal transplants.

Is there a reliable index of glomerular filtration rate in critically ill patients?

Assessment of renal function in critically ill patients is important for appropriate individualization of dosage regimens and nutrition, but is complicated by a high incidence of acute renal failure (ARF). The most common cause of ARF in intensive care unit (ICU) patients is hypoperfusion. Other causes of ARF include intrinsic injury, nephrotoxicity, and postrenal obstruction. ARF is associated with a decreased glomerular filtration rate (GFR), reduced or maintained urine output (nonoliguric renal failure), and alterations in other commonly obtained urinary indices. Twenty-four-hour or shorter urinary creatinine clearance studies may overpredict GFR as creatinine is both filtered and secreted. The use of serum creatinine in empiric predictive equations is impaired in ICU patients because of decreases in creatinine production due to immobilization and malnutrition or increases in creatinine production due to catabolic illnesses. Adjustment of empiric methods by employing lean body weight, ideal body weight, or corrected serum creatinine values has not been evaluated against uncorrected values in this population, but is routinely performed in clinical practice. Inulin and radiolabeled substances are not practical for routine clinical use and may overpredict GFR in ARF due to backleak of large molecular-weight substances through the tubules. Comparative clinical trials have shown essentially equivalent performance of empiric methods relative to 24-hour urinary creatinine clearance in adults. No studies have compared these methods to a reference method for determination of GFR. Until conclusive data become available, clinicians should cautiously compare results from at least two independent methods of assessment to estimate renal functional impairment in ICU patients.

The optimization of renal function in acute illness

The development of acute renal failure increases the morbidity, the mortality and the duration of hospital stay of all patients who are treated in intensive-care units. Consequently, the prevention of renal failure, and especially that of oliguric acute renal failure, has a high priority in the management of patients who are seriously-ill. The identification of risk factors, the pretreatment of patients who are in high-risk categories and the maintenance of adequate hydration, oxygenation, cardiac output and renal blood flow are the first-line priorities in management. The use of loop diuretic agents, mannitol and dopamine, separately or in combination, probably are effective prophylactic measures. They also may have therapeutic benefit in the maintenance of a non-oliguric state in the presence of acute renal failure, although there is less scientific support for this role. Such manoeuvres are worthy of trial before an oliguric state is accepted. They are more likely to be efficacious if they are instituted early.

Dopamine and new dopamine analogs: receptors and clinical applications

Division of dopamine (DA) receptors and alpha- and beta-adrenoceptors into two subtypes provides a pharmacological basis for the clinical use of DA and new DA receptor agonists in anesthesia and critical care medicine. First, differential receptor activation explains why three distinct cardiovascular and renal responses can be obtained at low, medium, and high infusion rates of DA. Low infusion rates, in which DA1 and DA2 receptors are activated, are being increasingly used to improve renal perfusion and to treat oliguric states. The medium dose range (activation of beta1-adrenoceptors) is used for treatment of heart failure. The high dose range (activation of alpha-adrenoceptors) is used for treatment of shock. Second, selective DA1 and relatively selective DA2 agonists and agonists with different combinations of DA and receptor activity other than DA have been synthesized and are being investigated for the treatment of congestive heart failure and hypertension. Some of these compounds could have advantages over DA for acute therapy. Future availability of these drugs in anesthesia and critical care settings will depend to a great extent on input from anesthesiologists concerning potential new uses and willingness to conduct clinical investigations.

A key to the literature of total parenteral nutrition: update 1987

This comprehensive bibliography is intended to enhance the education of the practitioner, student, and academician in the area of parenteral nutrition. This bibliography is not all-inclusive but serves as an update from the original published in 1983. Of particular note in this work is the addition of topics that reflect a growing interest in medical specialties with regard to patient nutritional status and support.

Pharmacology and therapeutic use of low-dose dopamine

The renal pharmacologic effects of intravenous dopamine in doses of 0.5-3.0 micrograms/kg/min include increases in renal blood flow, glomerular filtration rate, solute excretion, and urine flow. Clinical studies revealed that low-dose dopamine can reverse oliguria, but these studies were poorly controlled, were confounded by the use of other diuretics, had small patient populations, and often did not evaluate mortality or long-term renal function. When used in low doses, side effects are rarely seen. Because of dopamine's effect on hepatic and renal function, changes in drug clearance may occur. Low-dose dopamine may be considered in the early course of oliguric patients; however, specific advantages over other diuretic therapy have not been established.